News

Enlarge image

ResearchNetherlandsSwitzerland

Diagnosis: model beats doctor

22.04.2013 - Computers are better than doctors at predicting the outcomes and responses of lung cancer patients to treatment, say Dutch researchers.

The team around Cary Oberije presented its findings at the 2nd Forum of the European Society for Radiotherapy and Oncology (ESTRO) in Geneva. They said the model’s predictions remained superior to those of doctors even after the latter had seen the patient. The models use genomic information from previous patients to create a statistical formula that can be used to predict the probability of outcome and responses to treatment using radiotherapy with or without chemotherapy for future patients.

Having obtained predictions from the mathematical models, the researchers asked experienced radiation oncologists to predict the likelihood of lung cancer patients surviving for two years, or suffering from shortness of breath (dyspnea) and difficulty swallowing (dysphagia) at two points in time: 1) after they had seen the patient for the first time, and 2) after the treatment plan was made. At the first time point, the doctors predicted two-year survival for 121 patients, dyspnea for 139 and dysphagia for 146 patients. At the second time point, predictions were only available for 35, 39 and 41 patients respectively.

For all three predictions and at both time points, the mathematical models substantially outperformed the doctors' predictions, with the doctors' predictions being little better than those expected by chance.The researchers plotted the results on a special graph [1] on which the area below the plotted line is used for measuring the accuracy of predictions; 1 represents a perfect prediction, while 0.5 represents predictions that were right in 50% of cases, i.e. the same as chance. They found that the model predictions at the first time point were 0.71 for two-year survival, 0.76 for dyspnea and 0.72 for dysphagia. In contrast, the doctors' predictions were 0.56, 0.59 and 0.52 respectively.

"The number of treatment options available for lung cancer patients are increasing, as well as the amount of information available to the individual patient. It is evident that this will complicate the task of the doctor in the future," said Dr. Oberije from Maastricht University Medical Center. "If models based on patient, tumour and treatment characteristics already out-perform the doctors, then it is unethical to make treatment decisions based solely on the doctors' opinions. We believe models should be implemented in clinical practice to guide decisions."

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/diagnosis-computer-beats-doctor.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEWRON (CH)18.50 CHF9.14%
  • GENMAB (DK)1210.00 DKK5.68%
  • VALNEVA (F)2.42 EUR5.68%

FLOP

  • KAROLINSKA (S)7.30 SEK-3.95%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • SAREUM HOLDINGS (UK)0.60 GBP-3.23%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)51.61 USD52.6%
  • FLAMEL TECHNOLOGIES (F)12.71 USD34.6%

FLOP

  • MOLOGEN (D)1.80 EUR-28.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.60 GBP-20.0%

TOP

  • KARO BIO (S)31.10 SEK1893.6%
  • NICOX (F)11.17 EUR469.9%
  • SAREUM HOLDINGS (UK)0.60 GBP160.9%

FLOP

  • BB BIOTECH (D)44.69 EUR-84.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.7%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 26.07.2016